Cancer involves abnormal cells growing uncontrollably, invading nearby tissues, and spreading to other parts of the body through metastasis.
Send us all your questions or requests, and our expert team will assist you.
Diagnosing cancer in children is a careful, step-by-step process with two main goals: to understand exactly what type of cancer it is and to find out how far it has spread. Because these cancers can be aggressive and treatments can have long-term side effects, accuracy is essential. Doctors use a mix of imaging, tissue samples, and genetic tests. Staging systems for children are different from those used in adults and often include both how far the cancer has spread and specific biological risk factors.
Doctors usually start with non-invasive scans, but to confirm the diagnosis, they almost always need a sample of the tumor or bone marrow. This can be done with a needle or a small surgery. The sample is then tested in several ways, including looking at the cells under a microscope and checking for specific proteins and genetic changes. All this information helps the team decide how aggressive the treatment should be, placing each child into a low, intermediate, or high-risk group.
Imaging serves as the roadmap for diagnosis and surgical planning. Magnetic Resonance Imaging (MRI) is the gold standard for central nervous system and musculoskeletal tumors due to its superior soft-tissue contrast and lack of ionizing radiation. For abdominal tumors, Computed Tomography (CT) provides a rapid, high-resolution assessment of the mass and its relationship to major vessels, which is critical for surgical staging. Functional imaging has become indispensable; specific tracers are used to visualize tumor metabolic activity.
Metaiodobenzylguanidine (MIBG) scans are specific for neuroblastoma and use a radiolabeled norepinephrine analog to detect metastatic disease in bones and soft tissues. Positron Emission Tomography (PET) scans using fluorodeoxyglucose (FDG) map cellular metabolic activity and are used in the evaluation of lymphomas and sarcomas. These modalities enable the detection of metastatic deposits that are structurally normal but metabolically active, thereby significantly altering the stage and treatment approach.
The pathological diagnosis has moved beyond morphology. While the microscopic appearance of cells is the starting point, the final diagnosis rests on the molecular signature. Immunohistochemistry uses antibodies to detect specific proteins on the cell surface (e.g., CD99 for Ewing Sarcoma, Myogenin for Rhabdomyosarcoma). Flow cytometry is used in leukemia research, passing cells through a laser to analyze their surface markers and classify lineage (T-cell vs. B-cell).
Cytogenetics is the cornerstone of risk stratification. Techniques like Fluorescence In Situ Hybridization (FISH) and karyotyping detect chromosomal translocations and amplifications. For example, identifying the t(9;22) translocation (Philadelphia chromosome) in ALL changes the treatment to include tyrosine kinase inhibitors. The presence of MYCN amplification in neuroblastoma automatically classifies the disease as high-risk, regardless of the stage. Next-Generation Sequencing (NGS) is increasingly used to sequence the entire exome or genome of the tumor, identifying rare, actionable mutations that can be targeted with novel therapeutics.
Pediatric staging systems are unique because they often incorporate surgical resectability and biological markers into the stage itself. For Wilms tumor, the staging is based on the extent of the cancer at surgery whether it was resected entirely, spilled into the abdomen, or invaded blood vessels. For Neuroblastoma, the International Neuroblastoma Risk Group (INRG) staging system uses preoperative imaging-defined risk factors (IDRFs) to determine stage, independent of surgical outcome.
Risk stratification is a dynamic process. It is not static at diagnosis but evolves in response to therapy. In leukemia, the measurement of Minimal Residual Disease (MRD) at the end of induction therapy is the most powerful predictor of relapse. Patients who are MRD-negative are de-escalated to less toxic treatment, while those who are MRD-positive are escalated to more intensive regimens or stem cell transplant. This response-adapted staging is a key feature of modern pediatric oncology.
The field is moving toward less invasive diagnostics. Liquid biopsy involves analyzing blood or cerebrospinal fluid for Circulating Tumor DNA (ctDNA) or Circulating Tumor Cells (CTCs). This technology allows for the detection of specific mutations and the monitoring of disease burden without the need for repeated surgical biopsies. In retinoblastoma, ctDNA in the eye’s aqueous humor is being investigated to guide eye-sparing treatments. In lymphomas, ctDNA can track tumor clonal evolution, identifying the emergence of resistance mutations before clinical relapse.
Before initiating therapy, a comprehensive systemic evaluation is required to establish baseline organ function. This is critical because pediatric chemotherapy protocols utilize agents with known specific toxicities. Echocardiograms measure cardiac function before anthracycline use. Audiometry assesses hearing thresholds before cisplatin use. Glomerular filtration rate is calculated before high-dose methotrexate or ifosfamide. Neurocognitive testing sets a baseline for brain tumor patients. This baseline data is essential for monitoring toxicity during treatment and for long-term survivorship planning.
Send us all your questions or requests, and our expert team will assist you.
An MRI uses strong magnets and radio waves to create detailed images of soft tissues, such as the brain and muscles, without radiation, making it safer for repeated use in children. A CT scan uses X-rays to create quick, detailed images of bones and internal organs, but it involves ionizing radiation, so it is used more sparingly.
Risk stratification is a process where doctors categorize a child’s cancer into low, intermediate, or high risk based on the tumor’s genetics, spread, and the child’s age. This ensures that children with aggressive cancer get intense treatment, while those with less aggressive disease get lighter treatment to spare them from unnecessary side effects.
An MIBG scan is a nuclear medicine test used primarily to detect neuroblastoma. A small amount of radioactive material is injected into the vein, which attaches to neuroblastoma cells. This allows doctors to see exactly where the tumor is located in the body and if it has spread to bones or other tissues.
Bone marrow aspiration is necessary because leukemia and lymphoma start in the marrow, and many solid tumors like neuroblastoma spread there. Examining the liquid marrow and the solid bone piece allows doctors to quantify the number of cancer cells present and perform genetic tests on them.
Minimal Residual Disease refers to the smallest possible number of cancer cells that may remain in the body after treatment and cannot be seen under a microscope. Highly sensitive molecular tests measure MRD to determine if the treatment has worked completely or if more therapy is needed to prevent the cancer from coming back.
Knowing what a polyp is is key to understanding colorectal cancer risk. A polyp is a growth inside the colon or rectum. Most are harmless,
Are polyps scary in kids? Discover amazing facts about childhood health and find powerful ways to protect your family’s vital digestion. Polyps in the gut
Getting a cancer diagnosis can feel like a lot to handle. But, it’s key to take the right steps for the best treatment. Research indicates
Many think cancer leads to unintentional weight loss. But, some cancers cause weight gain. Obesity-related cancers, like breast cancer and endometrial cancer, are often linked
Nuclear medicine is key in finding and treating childhood diseases. Pediatric nuclear medicine is common and used often in kids’ care. Every year, almost 370,000
Leave your phone number and our medical team will call you back to discuss your healthcare needs and answer all your questions.
Your Comparison List (you must select at least 2 packages)
